GLP-1 agonists, which comprise short- and long-acting medications, have been linked to improved cardiovascular and glycaemic outcomes in patients with T2DM, and decrease in body weight in addition to having a high glycaemic efficacy [5]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.